Watch EXOZ. Know when insiders buy.
One email the day a filing lands. Free.
Work order
68
PASS · insiders 55, shorts 80
Insiders, 90 days
+$6K
net buying · 3 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $63.6MP/E —DIV YIELD —FCF YIELD -11.23%REV TTM —NET INCOME −$10.2MNET CASH —52W 4.40 – 16.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3M | −$2.9M | — | -0.33 | −$1.6M | −$1 | −$1.6M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$2.4M | −$2.4M | — | -0.28 | −$1.5M | $58K | −$1.6M | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.7M | −$2.7M | — | -0.31 | −$2M | $75K | −$2M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$2.5M | −$2.3M | — | -0.27 | −$1.9M | $13K | −$1.9M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$2.5M | −$2.4M | — | -0.28 | −$1.5M | $51K | −$1.6M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$2M | −$1.9M | — | -0.22 | −$1.1M | $31K | −$1.2M | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$2M | −$1.8M | — | -0.25 | −$5.7M | $210K | −$5.9M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$1.6M | −$1.7M | — | -0.27 | −$542K | $0 | −$542K | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$1.3M | −$1.4M | — | -0.22 | −$2.5M | $37K | −$2.6M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$1M | −$1M | — | -0.16 | $281K | $149K | $132K | Nov 13 |
| Q4 2023 · Dec 31derived | −$700 | — | — | −$985K | −$1.1M | — | -0.18 | −$783K | $110K | −$893K | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$392K | −$521K | — | -0.08 | — | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$9.7M | −$9.2M | — | -1.09 | −$6.5M | $170K | −$6.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$5.9M | −$5.9M | — | -0.89 | −$8.5M | $396K | −$8.9M | — | — |
| FY2023 · to Dec 31 | $70K | — | −$1.8M | −$2M | -2909.1% | -0.33 | −$1.2M | $289K | −$1.5M | — | — |
Every number comes from EXOZYMES INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.